Sort

Search

01/01/2022 A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction
Rao S.V., Kirsch B., Bhatt D.L., Coppolecchia R., Eikelboom J., James S.K., Jones W.S., Keller L., Hermanides R.S., Campo G., Ferreiro J.L., Mundl H., Alexander J.H., Hengstenberg C., Steinwender C., Alber H., Steringer-Mascherbauer R., Schober A., Auer J., Roithinger F.X., Von Lewinski D., Moertl D., Huber K., Coussement P., Hoffer E., Beauloye C., Janssens L., Vranckx P., De Raedt H., Vanassche T., Vrolix M., Rokyta R., Parenica J., Pelouch R., Motovska Z., Alan D., Kettner J., Polasek R., Cermak O., Sedlon P., Hanis J., Novak M., Belohlavek J., Horacek T., Leggewie S., Wenzel P., Vom Dahl J., Sievers B., Pulz J., Schellong S., Clemmensen P., Muller-Hennessen M., Rassaf T., Falukozi J., Ruzsa Z., Tomcsanyi J., Csanadi Z., Herczeg B., Koszegi Z., Vorobcsuk A., Kiss R., Baranyai C., Dezsi C., Merkely B., Lupkovics G., Rossini R., Scherillo M., Sergio Saba P., Calo L., Nassiacos D., Quadri G., Sciahbasi A., Silvio Marenzi G.C., Reimers B., Perna G.P., Sacca S., Fattore L., Brunelli C., Picchi A., Kuramochi T., Kondo K., Aoyama T., Kudoh T., Yamamoto T., Takaya T., Mukai Y., Fukui K., Morioka N., Ando K., Yamamuro A., Morita Y., Koga Y., Watanabe T., Sakamoto T., Shibasaki T., Maebuchi D., Takahashi A., Yonetsu T., Kakuta T., Nishina H., Oemrawsingh R., Dorman R., Oude Ophius T., Prins P., Al Windy N.Y.Y., Zoet-Nugteren S.K., Hermanides R., Van Eck M., Scherptong R., Cornel J.H., Damman P., Bech G., Torquay R., Kietselaer B., Grzelakowski P., Krzysztof D., Budaj A., Miekus P., Przybylski A., Zarebinski M., Balsam P., Szachniewicz J., Gierlotka M., Tycinska A., Iniguez Romo A., Fernandez Ortiz A., Carrasquer Cucarella A., Sanmartin Fernandez M., Sionis A., Bueno Zamora H., Ferreiro Gutierrez J.L., Almenar L., Ferreira Gonzalez I., Pascual Figal D.A., Almendro Delia M., Jimenez Fernandez M., Skeppholm M., Zedigh C., Angeras O., Lauermann J., Erlinge D., Gustafsson R., Mooe T., Utreras A., James S., Grimfjard P., Pedrazzini G., Mach F., Fournier S., Haegeli L., Beer J.H., Leibundgut G., Kobza R., Kaiser C., Kunadian V., Al-Lamee R., Gorog D., Khan S., Trevelyan J., Toor I., Smith J., Purushottam B., Treasure C., Arena F., Vedere A., Henderson D., Gilani S., Jones A., Carrillo-Jimenez R., Gillespie E., Marhefka G., Wang D., Olson C., Bloom S., Iftikhar F., Brabham D., McGinty J., Thompson C., Talano J., Ginete W., Williams M., Masud A., Ariani M., Bitar F., Wang T., Samuelson B.. A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction. CIRCULATION. 2022; 146(16)DOI:10.1161/CIRCULATIONAHA.122.061612. PMID:36030390. IF:37.800(Q1/1D).
01/01/2022 Impact of increased kidney function on clinical and biological outcomes in real-world patients treated with Direct Oral Anticoagulants
Corrochano M., Acosta-Isaac R., Plaza M., Muñoz R., Mojal S., Moret C., Souto J.C.. Impact of increased kidney function on clinical and biological outcomes in real-world patients treated with Direct Oral Anticoagulants. PLoS One. 2022; 17(12)DOI:10.1371/journal.pone.0278693. PMID:36490245. IF:3.700(Q2/4D).
01/01/2022 Comparación de dos programas de posprocesamiento de imágenes de cardiorresonancia magnética en un modelo porcino de infarto de miocardio
Radike M., Ben-Aicha S., Gutiérrez M., Hidalgo A., Badimón L., Vilahur G.. Comparación de dos programas de posprocesamiento de imágenes de cardiorresonancia magnética en un modelo porcino de infarto de miocardio. REVISTA ESPANOLA DE CARDIOLOGIA. 2022; 76(2)DOI:10.1016/j.recesp.2022.06.007. PMID:35809893. IF:5.900(Q1/3D).
01/01/2022 European Society of Cardiology quality indicators for the prevention and management of cancer therapy-related cardiovascular toxicity in cancer treatment
Lee G.A., Aktaa S., Baker E., Gale C.P., Yaseen I.F., Gulati G., Asteggiano R., Szmit S., Cohen-Solal A., Abdin A., Jurczak W., Garrido Lopez P., Sverdlov A.L., Tocchetti C.G., Barac A., Parrini I., Zamorano P., Iakobishvili Z., Pudil R., Badimon L., Kirby A.M., Blaes A.H., Farmakis D., Curigliano G., Stephens R., Lyon A.R., Lopez-Fernandez T.. European Society of Cardiology quality indicators for the prevention and management of cancer therapy-related cardiovascular toxicity in cancer treatment. European Heart Journal-Quality of Care and Clinical Outcomes. 2022; 9(1)DOI:10.1093/ehjqcco/qcac070. PMID:36316010. IF:5.200(Q2/3D).